Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study - 05/08/11
, Sunil K. Agarwal, MD, MPH b, Marietta Ambrose, MD c, Aaron R. Folsom, MD, MPH a, Elsayed Z. Soliman, MD, MSc, MS d, Alvaro Alonso, MD, PhD a, eRésumé |
Background |
The metabolic syndrome (MetSyn) has been implicated in the development of atrial fibrillation (AF); however, knowledge of this association among blacks is limited.
Methods |
We determined the risk of incident AF through December 2005 in relation to baseline (1987-1989) MetSyn status in 15,094 participants of the Atherosclerosis Risk in Communities study.
Results |
Over a mean follow-up of 15.4 years, 1,238 incident AF events were identified. The hazard ratio (HR) for AF among individuals with, compared to those without, the MetSyn was 1.67 (95% CI 1.49-1.87), and associations did not differ by race (P for interaction = .73). The population attributable risk of AF from the MetSyn was 22%. The multivariable-adjusted HRs (95% CI) for each MetSyn component were 1.95 (1.72-2.21) (elevated blood pressure), 1.40 (1.23-1.59) (elevated waist circumference), 1.20 (1.06-1.37) (low high-density lipoprotein cholesterol), 1.16 (1.03-1.31) (impaired fasting glucose), and 0.95 (0.84-1.09) (elevated triglycerides). A monotonically increasing risk of AF with increasing number of MetSyn components was observed, with an HR of 4.40 (95% CI 3.25-5.94) for those with all 5 MetSyn components compared to those with 0 components.
Conclusion |
In this large cohort, the MetSyn and most of its components were associated with a higher risk of AF in both blacks and whites. Given the high prevalence of the MetSyn, strategies to prevent its development or to control individual components may reduce the burden of AF.
Le texte complet de cet article est disponible en PDF.Plan
Vol 159 - N° 5
P. 850-856 - mai 2010 Retour au numéro
Article précédent
- Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) program
- Christopher M. O'Connor, Alan B. Miller, John E.A. Blair, Marvin A. Konstam, Patricia Wedge, Maria C. Bahit, Peter Carson, Markus Haass, Paul J. Hauptman, Marco Metra, Ron M. Oren, Richard Patten, Ileana Piña, Sherryn Roth, Jonathan D. Sackner-Bernstein, Brian Traver, Thomas Cook, Mihai Gheorghiade, for the Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators
- Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Atrial Fibrillation (GISSI-AF) trial
- Marcello Disertori, Federico Lombardi, Simona Barlera, Roberto Latini, Aldo P. Maggioni, Prisca Zeni, Giuseppe Di Pasquale, Franco Cosmi, Maria Grazia Franzosi, on behalf of the GISSI-AF Investigators g
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?